<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056611</url>
  </required_header>
  <id_info>
    <org_study_id>CR108662</org_study_id>
    <secondary_id>53718678RSV2005</secondary_id>
    <secondary_id>2019-001551-39</secondary_id>
    <nct_id>NCT04056611</nct_id>
  </id_info>
  <brief_title>Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)</brief_title>
  <acronym>FREESIA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of JNJ-53718678 on the development of
      respiratory syncytial virus (RSV) lower respiratory tract infection (LRTIs) in adult
      hematopoietic stem cell transplant (HSCT) recipients with RSV upper RTI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RSV is recognized as major respiratory pathogen in infants and young children and causes
      upper and lower respiratory illness among all age groups, often going undiagnosed.
      Immunocompromised (IC) participants have a reduced ability to combat infection due to an
      impaired or weakened immune system. Within the IC population, HSCT recipients are generally
      regarded as having a particularly high risk for more severe disease caused by RSV,
      representing a substantial unmet need for antiviral treatment of RSV infections in this
      participant population. JNJ-53718678 is an investigational, potent, small molecule,
      respiratory syncytial virus (RSV)-specific fusion inhibitor. The study will include a
      Screening Period (Day -2 to Day 1), a Treatment Period (Day 1 to Day 21), and a Follow-up
      Period (1 year). Assessments like chest X-ray, pulse/heart rate, respiratory rate,
      electrocardiogram (ECG), etc will be performed. Safety and efficacy will be assessed through
      the study. The total study duration for each participant will be approximately 49 days.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Urgent Safety Measure
  </why_stopped>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants who Develop Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>The proportion of participants who develop RSV LRTI through Visit Day 28 per the Endpoint Adjudication Committee (EAC) assessment will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Develop RSV-associated Lower Respiratory Tract Complication (LRTC)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>The proportion of participants who develop RSV-associated LRTC through Visit Day 28 per the EAC's assessment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormal Clinical Laboratory Findings</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Percentage of participants with abnormal clinical laboratory findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormal Electrocardiograms (ECGs) Findings</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Percentage of participants with abnormal ECGs findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Abnormal Vital Signs Findings</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Percentage of participants with abnormal vital signs findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) and/or Death, in Participants who Develop RSV LRTI or RSV-associated LRTC per the EAC's Assessment</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>The proportion of participants progressing to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) and/or death, in participants who develop RSV LRTI or RSV-associated LRTC per the EAC's assessment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive) and/or Death, (all-cause Mortality)</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Proportion of participants progressing to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) and/or death, (all-cause mortality) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Death (All-cause Mortality), in Participants who Develop RSV LRTI or RSV-associated LRTC per the EAC's Assessment</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Proportion of participants progressing to death (all-cause mortality), in participants who develop RSV LRTI or RSV-associated LRTC per the EAC's assessment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Death (All-cause Mortality)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of participants progressing to death (all-cause mortality) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive), in Participants who Develop RSV LRTI or RSV-associated LRTC per the EAC's Assessment</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Proportion of participants progressing to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive), in participants who develop RSV LRTI or RSV-associated LRTC per the EAC's assessment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Progressing to Respiratory Failure (of any Cause) Requiring Mechanical Ventilation (Invasive or Noninvasive)</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Proportion of participants progressing to respiratory failure (of any cause) requiring mechanical ventilation (invasive or noninvasive) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Supplemental Oxygen (O2) Free Days Through Day 28</measure>
    <time_frame>Through Day 28</time_frame>
    <description>Number of supplemental O2 free days will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Supplemental Oxygen Requirement</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Incidence of supplemental oxygen requirement in participants will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Supplemental Oxygen</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Duration of supplemental oxygen requirement in participants will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Respiratory Rate</measure>
    <time_frame>Baseline up to 49 days</time_frame>
    <description>Change from baseline in respiratory rate as measured by the investigator during scheduled visits will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Heart Rate</measure>
    <time_frame>Baseline up to 49 days</time_frame>
    <description>Change from baseline in heart rate as measured by the investigator during scheduled visits will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Peripheral Capillary Oxygen Saturation (SpO2)</measure>
    <time_frame>Baseline up to 49 days</time_frame>
    <description>Change from baseline in SpO2 as measured by the investigator during scheduled visits will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Temperature</measure>
    <time_frame>Baseline up to 49 days</time_frame>
    <description>Change from baseline in body temperature as measured by the investigator during scheduled visits will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Hospitalized (of Participants who Were not Hospitalized at Baseline)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of participants hospitalized (of participants who were not hospitalized at baseline) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Re-hospitalized</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Proportion of participants re-hospitalized (of participants who were hospitalized at baseline and discharged during the study and of participants who were not hospitalized at baseline, required hospitalization, and were discharged during the study) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospital Stay</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Total length of hospital stay (time in hospital from first dosing) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time in the Intensive Care Unit (ICU)</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Total time in the ICU (time in ICU from first dosing) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 and Grade 4 Adverse Events (AEs)</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Incidence of Grade 3 and Grade 4 AEs will be assessed by system organ class where Grade 3: Severe and Grade 4: Life-threatening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Respiratory AEs</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Incidence of respiratory AEs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Thoracic-related AEs</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Incidence of thoracic-related AEs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Antibiotic use in Participants who Develop and in Those who do not Develop RSV LRTI or RSV-Associated LRTC per the EAC's Assessment</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Incidence of antibiotic use in participants who develop and in those who do not develop RSV LRTI or RSV-associated LRTC per the EAC's assessment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Symptoms as Assessed by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Symptom Scale</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Time to resolution of symptoms, assessed through an instrument for participant-reported symptoms (RiiQ Symptom Scale) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Severity of Symptoms Reported by Participants in the RiiQ Symptom Scale Through Day 28</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Change from baseline in severity of symptoms reported by participants in the RiiQ symptom scale through Day 28 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Respiratory Illness as Assessed by Patient Global Impression of Severity (PGI-S) Scale</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Time to resolution of respiratory illness, through the PGI-S Scale, will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Impression of Health (PGI-H) Scale Through Day 28</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Change from baseline in PGI-H scale through Day 28 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Impression of Change (PGI-C) Scale Through Day 28</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Change from baseline in PGI-C scale through Day 28 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours Postdose (AUC [0-24]) of JNJ-53718678</measure>
    <time_frame>Up to 24 hours postdose (on Days 1 and 8)</time_frame>
    <description>AUC (0-24h) is defined as area under the plasma concentration-time curve from time 0 to 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration (Ctrough) of JNJ-53718678</measure>
    <time_frame>Predose on Days 1 and 8</time_frame>
    <description>Ctrough is defined as the observed plasma concentration before dosing or at the end of the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of JNJ-53718678</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax is defined as the maximum observed plasma concentration of JNJ-53718678 in the dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Plasma Concentration-time Data of JNJ-53718678 and Antiviral Activity</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>The potential association of plasma concentration-time data of JNJ-53718678 with antiviral activity (RSV viral kinetics) will be analyzed. Association will be analyzed using (non)-linear mixed-effects models in a tabular and/or graphical display.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Plasma Concentration-time Data of JNJ-53718678 and Safety Parameters</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>The potential association of plasma concentration-time data of JNJ-53718678 with selected safety (including AEs and laboratory abnormalities) parameters will be analyzed. Association will be analyzed using (non)-linear mixed-effects models in a tabular and/or graphical display.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of Plasma Concentration-time Data of JNJ-53718678 and Clinical Outcomes</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>The potential association of plasma concentration-time data of JNJ-53718678 with clinical outcomes (proportion of participants developing LRTI) will be analyzed. Association will be analyzed using (non)-linear mixed-effects models in a tabular and/or graphical display.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Viral Load and Change from Baseline Over Time</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>RSV viral load and change from baseline over time will be measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay in the mid-turbinate nasal swab specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Viral Load AUC from Immediately Prior to First Dose of Study Drug (Baseline) Through Days 8, 11, 15, 22 and 28</measure>
    <time_frame>Baseline up to Days 8, 11, 15, 22 and 28</time_frame>
    <description>RSV viral load AUC will be determined by quantitative qRT-PCR assay of nasal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Undetectable RSV Viral Load</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Time to undetectable RSV viral load (per the detection limit of the assay used in the study) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Undetectable RSV Viral Load at Each Timepoint</measure>
    <time_frame>Up to 49 days</time_frame>
    <description>Proportion of participants with undetectable RSV viral load at each time point throughout the study will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for the Health-related Quality of Life (HRQOL) as Assessed by 5-level EuroQol 5-Dimension (EQ-5D-5L) Through Day 28</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Change from baseline for the HRQOL assessment as assessed through the EQ-5D-5L through Day 28 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for the HRQOL as Assessed by RiiQ Impact Scales Through Day 28</measure>
    <time_frame>Baseline up to Day 28</time_frame>
    <description>Change from baseline for the HRQOL assessment as assessed through RiiQ impact scales through Day 28 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the RSV F Gene Sequence</measure>
    <time_frame>Baseline up to 49 days</time_frame>
    <description>Change from baseline in the RSV F gene sequence will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Adult cohort: JNJ-53718678 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants greater than or equal to (&gt;=) 18 to less than or equal to (&lt;=) 75 years of age will receive 250 milligram (mg) JNJ-53718678 twice daily (bid) for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg once daily (qd) for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescent cohort: JNJ-53718678 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants &gt;=13 to &lt;18 years of age will receive 250 mg JNJ-53718678 bid for 21 days (without coadministration with moderate or strong CYP3A4 inhibitors), or 125 mg JNJ-53718678 bid for 21 days (coadministered with moderate or strong CYP3A4 inhibitors with the exception of posaconazole), or 125 mg qd for 21 days (when coadministered with posaconazole), or matching placebo for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-53718678 250 mg</intervention_name>
    <description>JNJ-53718678 250 mg will be administered orally.</description>
    <arm_group_label>Adolescent cohort: JNJ-53718678 or Placebo</arm_group_label>
    <arm_group_label>Adult cohort: JNJ-53718678 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered orally.</description>
    <arm_group_label>Adolescent cohort: JNJ-53718678 or Placebo</arm_group_label>
    <arm_group_label>Adult cohort: JNJ-53718678 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-53718678 125 mg</intervention_name>
    <description>JNJ-53718678 125 mg will be administered orally.</description>
    <arm_group_label>Adolescent cohort: JNJ-53718678 or Placebo</arm_group_label>
    <arm_group_label>Adult cohort: JNJ-53718678 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received an autologous or allogeneic hematopoietic stem cell transplant (HSCT) using
             any conditioning regimen

          -  Absolute lymphocyte count (ALC) less than (&lt;) 1,000 cells/microliter (mL)

          -  Participant has laboratory confirmed RSV diagnosis within 48 hours of randomization

          -  New onset of at least 1 of the following respiratory symptoms within 4 days prior to
             the anticipated start of dosing nasal congestion, rhinorrhea, cough or pharyngitis
             (sore throat), and/or worsening of one of these chronic (associated with previously
             existing diagnosis, example, chronic rhinorrhea, seasonal allergies, chronic lung
             disease) respiratory symptoms within 4 days prior to the anticipated start of dosing

          -  Peripheral capillary oxygen saturation (SpO2) greater than or equal to (&gt;=) 92 percent
             (%) on room air

        Exclusion Criteria:

          -  Admitted to the hospital primarily for a lower respiratory tract disease of any cause
             as determined by the investigator

          -  Requires supplemental oxygen at Screening or any time between Screening and
             randomization

          -  Documented to be positive for other respiratory viruses (limited to influenza,
             parainfluenza, human rhinovirus, adenovirus, human metapneumovirus, or coronavirus)
             within 7 days prior to or at the Screening visit, if determined by local SOC testing
             (additional testing is not required)

          -  Clinically significant bacteremia or fungemia within 7 days prior to or at Screening
             that has not been adequately treated, as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital - Hematology/oncology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health Cancer Institute</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville VA Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College Of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Español De Bahia Blanca</name>
      <address>
        <city>Bahia Blanca</city>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de La Plata</name>
      <address>
        <city>Ciudad De La Plata</city>
        <zip>B1900AX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado-Universitario de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital El Cruce</name>
      <address>
        <city>Florencio Varela</city>
        <zip>B1888AAE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Mayo de UMCB</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IHE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Limburg</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Amor - Barretos</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal De Minas Geraisnas Gerais</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cepon - Centro De Pesquisas Oncologicas</name>
      <address>
        <city>Florianopolis</city>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Walter Cantidio</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-372</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Amaral Carvalho</name>
      <address>
        <city>Jau</city>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncobio</name>
      <address>
        <city>Nova Lima</city>
        <zip>34.006-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-007</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quinta D'or</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20941-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01308-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBCC Instituto Brasileiro de Controle do Cancer</name>
      <address>
        <city>Sao Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base de São José do Rio Preto</name>
      <address>
        <city>São José do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Beneficencia Portuguesa</name>
      <address>
        <city>São Paulo</city>
        <zip>01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Antonio Prudente</name>
      <address>
        <city>São Paulo</city>
        <zip>01508-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Sveti Georgi'-Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hopital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes hôtel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Medizin der Johann-Gutenberg-Unversitaet - III. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKM Knochenmarktransplantationszentrum</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Campus</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>57261</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky (Ichilov) Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera San Martino - IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele HSR Istituto Scientifico Universitario San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Fondazione Univ. Policlinico Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kumamoto Medical Center</name>
      <address>
        <city>Kumamoto-City</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagano Red Cross Hospital</name>
      <address>
        <city>Nagano</city>
        <zip>380-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daiichi Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Narita Hospital</name>
      <address>
        <city>Narita</city>
        <zip>286-8523</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine Hospital</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka-Shi</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Shibuya</city>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang Jaya</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penang General Hospital</name>
      <address>
        <city>Georgetown</city>
        <zip>10190</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunway Medical Centre</name>
      <address>
        <city>Petaling Jaya</city>
        <zip>41650</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sverdlovsk Regional Clinical Hospital #1</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirov Research Institute of Hematology</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Research-Clinical Centre of Pediatric Hematology, Oncology and Immunology n.a.D.Rogachev</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.52</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samara State Medical Univeristy</name>
      <address>
        <city>Samara</city>
        <zip>443099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution Scientific Research Institute of Oncology n.a. Petrov N.N.&quot; of the</name>
      <address>
        <city>St Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Petersburg Clinical Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. I Politecni La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSELSPITAL, Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

